Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.43 |
| ▸ | IL2 | P60568 | 2/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 9/20 | 0.42 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435907 | 0.91 | TNIK (0.44) | MAP4K1IL2TNIKPAK1PAK4 | |
| SCHEMBL31435905 | 0.91 | TNIK (0.44) | MAP4K1IL2TNIKPAK1PAK4 | |
| SCHEMBL31435981 | 0.89 | MAP4K1 (0.47) | MAP4K1IL2TNIKKIT | |
| SCHEMBL31435986 | 0.82 | KIT (0.47) | MAP4K1IL2TNIKKITPAK1 | |
| SCHEMBL31435985 | 0.82 | KIT (0.47) | MAP4K1IL2TNIKKITPAK1 | |
| SCHEMBL31435910 | 0.81 | MAP4K1 (0.50) | MAP4K1IL2TNIKKIT | |
| SCHEMBL31435943 | 0.80 | KIT (0.52) | MAP4K1IL2TNIKKITALK | |
| SCHEMBL31435982 | 0.78 | KIT (0.49) | MAP4K1IL2TNIKKITALK | |
| SCHEMBL31435923 | 0.77 | PTPN11 (0.40) | ALK | |
| SCHEMBL31435903 | 0.76 | KIT (0.51) | MAP4K1IL2KITALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2025-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | TYRO3, TH, TYR | MAP4K1 438/4885IL2 4619/4885TNIK 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.